Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

Completed NCT05678517

Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD

Conditions: Age-Related Macular Degeneration

Sex: All

Ages: 50 Years – N/A

Enrollment: 47

Sponsor: Semmelweis University

Location: Hungary

The aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-VEGF therapy in patients with exudative AMD.

Same as the original VIEW2 study (NCT00637377)Finished VIEW 2 study

Interested in this study? View the official listing for contact and enrollment details.

Source: ClinicalTrials.gov (NCT05678517). StuddyBuddy aggregates publicly available trial information.